Lung Cancer

Circulating tumor DNA clearance of EGFR mutation may be predictive of prolonged progression-free survival for patients with EGFR-mutant, MET-amplified non–small cell lung cancer with detectable ctDNA at baseline.

Balazs Halmos, MD, MS, discusses recent advancements made in non–small cell lung cancer.

The China National Medical Products Administration has accepted a supplemental new drug application for tislelizumab in combination with chemotherapy for the frontline treatment of patients with advanced nonsquamous non–small cell lung cancer.

The combination of atezolizumab plus carboplatin/etoposide continued to demonstrate an improvement in overall survival versus chemotherapy alone as a frontline treatment for patients with extensive-stage small cell lung cancer.

Robert Rintoul, BSc, MB ChB, PhD, FRCP, discusses the importance of minimal residual disease assessment in patients with non–small cell lung cancer.

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

Roy S. Herbst MD, PhD, discusses the ADAURA trial and the impressive data seen with adjuvant osimertinib and highlights ongoing research efforts being made with the agent in lung cancer.

The United Kingdom’s National Institute for Health and Care Excellence has recommended entrectinib (Rozlytrek) as a treatment option for ROS1-positive advanced non–small cell lung cancer in adults who have not received prior treatment with ROS1 inhibitors.

The FDA has approved lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer with disease progression, following platinum-based chemotherapy.

The 4-drug ABCP regimen improved survival while maintaining good health-related quality of life in patients with nonsquamous non–small cell lung cancer, according to patient-reported outcomes from the phase 3 IMpower150 trial.

Jean Lopategui, MD, discusses the evolution of targeted therapies in non–small cell lung cancer.

Hatim Husain, MD, discusses common misconceptions that still exist with regard to lung cancer.

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

David R. Gandara, MD, an esteemed lung cancer specialist and 2017 Giants of Cancer Care® award winner, views himself not only as a physician-scientist, but also as an educator and communicator.

The Data and Safety Monitoring Board has advised that the phase 3 DUBLIN-3 trial of the antineoplastic agent plinabulin in patients with advanced or metastatic non–small cell lung cancer who have progressed on standard-of-care therapy can continue without any modifications.

Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.

Delvys Rodriguez-Abreu, MD, discusses the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.

The addition of durvalumab to standard chemotherapy continued to demonstrate an improvement in overall survival for patients with treatment-naïve extensive-stage small cell lung cancer.